Why the study?
Does the implantable cardioverter defibrillator (ICD) improve survival compared to drug therapy (amiodarone or sotalol) in patients who have survived an out-of-hospital cardiac arrest or have syncopal or hemodynamically significant ventricular tachycardia?
Does the implantable cardioverter defibrillator (ICD) improve survival compared to drug therapy (amiodarone or sotalol) in patients who have survived an out-of-hospital cardiac arrest or have syncopal or hemodynamically significant ventricular tachycardia?
This review highlights that ICDs provide a survival advantage over antiarrhythmic drugs in secondary prevention of sudden cardiac death, particularly in patients with reduced ejection fraction.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
David S. Cannom (1998) conducted a review in Out-of-hospital cardiac arrest or syncopal/hemodynamically significant ventricular tachycardia. Implantable cardioverter defibrillator (ICD) vs. Drug therapy (amiodarone or sotalol) was evaluated on Survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: